1.Ejiri H, Tanaka K, Kimura H, Saito H, Shimabukuro M, Asahi K, Watanabe T, Kazama JJ. Predictive values of four nutritional indices for adverse outcomes in patients with hypertension. Clin Exp Nephrol 2025;29:433-443. pubmed
2.Fujiwara M, Kimura H, Tanaka T, Saito H, Shimabukuro M, Asahi K, Watanabe T, Kazama JJ. Association between malnutrition and adverse renal outcomes in patients with type 2 diabetes. J Diabetes Investig 2025;16:100-107. pubmed
3.Holmes-Truscott E, Litterbach E, Søholm U, Agius PA, Alzubaidi H, Bodziony V, Bresolin J, Fletcher K, Garza M, Joiner KL, Puhl RM, Shimabukuro M, Syron L, Takaike H, Vallis M, Verry H, Halliday JA, Manallack SL, Skinner TC, Speight J. Experiences of diabetes stigma among adults with type 1 and type 2 diabetes: a multi-study, multi-country, secondary analysis. Diabet Med 2025;42:e70082. pubmed
4.Kawashima R, Meller C, Suzuki M, Kato S, Horita S, Hidema S, Misaka S, Hosoya M, Go H, Kobayashi K, et al. Kir6.2 channel activity is regulated by interaction of transmembrane domains 1 and 2 through I167 in the bundle-crossing gate. Physiol Rep 2025;13:e70481. pubmed
5.Kimura H, Tanaka K, Saito H, Kazama S, Shimabukuro M, Asahi K, Watanabe T, Kazama JJ. Association of red blood cell distribution width/albumin ratio with renal prognosis among patients with type 2 diabetes mellitus: A retrospective cohort study. J Diabetes Investig 2025;16:1829-1835. pubmed
6.Kobashi Y, Takebayashi Y, Tsubokura M, Ohira T, Sakai A, Okazaki K, Shimabukuro M, Ohto H, Yasumura S. Longitudinal health checkup access pattern following a triple disaster using latent class growth analysis: The Fukushima Health Management Survey. Public Health 2025;244:105755. pubmed
7.Ma E, Ohira T, Fukasawa M, Shirafuji A, Matsuzaki K, Hosoya M, Yasumura S, Shimabukuro M. Obesity indices in identifying type 2 diabetes mellitus: a longitudinal study of the Fukushima Health Database 2015-2021. Diabetol Metab Syndr 2025;17:236. pubmed
8.Nakada K, Tanaka K, Kimura H, Saito H, Oda A, Watanabe S, Shimabukuro M, Asahi K, Watanabe T, Kazama JJ. High-density lipoprotein cholesterol and kidney disease progression in patients with type 2 diabetes mellitus: The Fukushima Cohort Study. BMJ Open Diab Res Care 2025;13:e005581. pubmed
9.Sakai A, Nakano H, Hashimoto K, Okazaki K, Nagao M, Shimabukuro M, Ohira T, Ishikawa T, Tsubokura M, Hosoya M, Takahashi A, J JK, Hashimoto S, Watanabe K, Kobashi G, Satoh H, Takahashi H, Hayashi F, Sato S, Ohto H, Yasumura S. Changes in peripheral blood test results among adults in the six years following the Great East Japan Earthquake: the Fukushima Health Management Survey. Fukushima J Med Sci 2025;71:213–26. pubmed
10.Sato A, Tanaka K, Kimura H, Saito H, Shimabukuro M, Asahi K, Watanabe T, Kazama JJ. Nutritional status and new onset of chronic kidney disease. Clin Nutr ESPEN 2025;70:274-280. pubmed
11.Takiguchi Y, Tsutsumi R, Shimabukuro M, Tanabe H, Kawakami A, Hyodo M, Shiroma K, Saito H, Matsuo M, Sakaue H. Urinary titin as a biomarker of sarcopenia in diabetes: a propensity score matching analysis. J Endocrinol Invest 2025;48:1041-1056. pubmed
12.Tanabe H, Takiguchi Y, Tsutsumi R, Shiroma K, Hyodo M, Izumi-Mishima Y, Nomura K, Matsuo M, Sakaue H, Shimabukuro M. Prediction of sarcopenia onset in type 2 diabetes using urinary titin levels: A Japanese prospective cohort study. Diabetes Care 2025;48:1844. pubmed
13.Tanaka A, Vaduganathan M, Imai T, Okada Y, Sonoda S, Torimoto K, Suwa S, Teragawa H, Miyazono M, Fukuda M, Yonezu K, Takahashi N, Yoshida Y, Tanaka K, Shimabukuro M, Hotta Y, Moroi M, Niikura H, Kida K, Yokota K, Fukuda D, Tanabe K, Horiuchi Y, Toyoda S, Taguchi I, Yoshida H, Miyoshi T, Nangaku M, Shibata H, Node K, on behalf of the F-SI. Effects of finerenone on arterial stiffness and cardiorenal biomarkers in patients with type 2 diabetes and chronic kidney disease: a randomised placebo-controlled mechanistic trial (FIVE-STAR). Cardiovasc Diabetol 2025;24:454. pubmed
14.Tanaka K, Kimura H, Saito H, Shimabukuro M, Asahi K, Watanabe T, Kazama JJ. The relationship of the ratio of platelet distribution width to serum albumin with kidney disease progression in patients with hypertension. Sci Rep 2025;15:20480. pubmed
15.Teragawa H, et al. Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial. Cardiovasc Diabetol 2025;24:190. pubmed
